R405--Generation of targeted SRT1720 Compount

The Veterans Health Administration (VHA), Office of Research and Development (R&D), Regional Procurement Office (RPO) East in Pittsburgh, PA intends to negotiate on a sole source basis with Novosteo, Inc. for services directly related to the generation of targeted SRT 1720 compound.

The requirement is for the contractor to generate the targeted SRT1720 compound to treat fracture surgery. The targeting is to the fracture site and this compound is proprietary. Novosteo, Inc. has developed this molecule for 4 years and developed the design and synthesis of this molecule.

These services will be directly supporting the R&D Laboratory at the Indianapolis VA Medical Center in Indianapolis, Indiana. This contract will have a base period of 12 months with 1 option period.

This procurement is being conducted IAW FAR 6.302-1, Only one responsible source and no other contractors will satisfy agency requirements; and VHAPM Part 813.106-1(b), Other Than Full and Open Competition less than SAT for Open Market Items.

This notice of intent is not a request for competitive proposals. However, any responsible source who believes it is capable of meeting the requirement may submit a capability statement and supporting documentation to the Contracting Officer no later than Friday, November 25, 2022, 5:00 PM, EST. Interest/capability statements may be sent by email to Mr. Robin Simmons at robin.simmons@va.gov. No telephone responses will be accepted. A determination not to compete the proposed requirement based upon the responses to this notice is solely within the discretion of the Government.